Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| 제품번호 | 종 | 제품 설명 | 구조 | 순도 | 특징 |
|---|---|---|---|---|---|
| CHEK-STP114 | Human | NY-ESO-1 specific TCR-HEK293 cell line |
FACS analysis NY-ESO-1 specific TCR on NY-ESO-1 specific TCR-HEK293 cell line.
FACS assay shows that PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein can bind to NY-ESO-1 specific TCR-HEK293 cell line. NY-ESO-1 specific TCR-HEK293 cell line was red line, Negative control HEK293 cells was grey line (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Cancer vaccine NY-ESO-1 (Ludwig Institute/Peking University/Jewim Pharmaceutical) | Phase 2 Clinical | Ludwig Institute For Cancer Research | Liver Neoplasms; Melanoma | Details | |
| Anti-NY-ESO-1 TCR-T cell theray (Shenzhen BinDeBio) | Phase 2 Clinical | Shenzhen Bindebio Ltd | Stomach Neoplasms; Esophageal Neoplasms; Glioma; Carcinoma, Hepatocellular | Details | |
| Anti-NY-ESO-1 murine TCR transduced autologous peripheral blood lymphocytes (Albert Einstein College of Medicine/NCI) | Phase 1 Clinical | Albert Einstein College Of Medicine Inc, National Cancer Institute | Neoplasms | Details | |
| Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes (Roswell) | CD8-TCR-T cells; NY-ESO-1/CD8/HL AA2.1-19305dp-TCR-T cells | Phase 2 Clinical | Roswell Park Cancer Institute | Neoplasms | Details |
| LYL-132 | LYL-132; GSK-4427296 | Phase 1 Clinical | Lyell Immunopharma Inc | Solid tumours; Neoplasms | Details |
| GSK-3845097 | GSK-3845097; GSK3845097 | Glaxosmithkline Plc | Details | ||
| GSK-3901961 | GSK-3901961; GSK3901961 | Glaxosmithkline Plc | Details | ||
| HBI-0201-ESO TCRT | HBI-0201-ESO TCRT | Phase 2 Clinical | Hadassah Medical Organization | Ovarian Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Sarcoma, Synovial; Sarcoma; Neuroblastoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis | Details |
| mipetresgene autoleucel | TBI-1301 | Phase 2 Clinical | Takara Bio Inc | Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Lung Neoplasms; Melanoma | Details |
| NY-ESO-1 TCR Engineered T Cells and HSCs (Roswell Park Cancer Institute) | Phase 1 Clinical | Roswell Park Cancer Institute | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details | |
| NY-ESO-1 TCR | Phase 2 Clinical | Kite Pharma, National Cancer Institute | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Sarcoma, Synovial; Sarcoma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Meningioma | Details | |
| Letetresgene autoleucel | GSK-3377794; GSK-794 | Phase 2 Clinical | Adaptimmune Llc | Ovarian Neoplasms; Neoplasms; Multiple Myeloma; Melanoma | Details |
| TCR Affinity Enhancing Specific T cell Therapy | TAEST-16001 | Phase 2 Clinical | Guangzhou Xiangxue Pharmaceutical Co Ltd, Guangzhou Institute Of Respiratory Health | Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Urinary Bladder Neoplasms; Osteosarcoma; Sarcoma; Breast Neoplasms; Bone Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Rasdegafusp alfa | CDX-1401 | Phase 2 Clinical | Ludwig Institute For Cancer Research | Prostatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Uterine Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Skin Melanoma; Brain Neoplasms; Oligodendroglioma; Urinary Bladder Neoplasms; Neoplasms; Glioblastoma; Colonic Neoplasms; Leukemia, Myelomonocytic, Chronic; Anemia, Refractory; Myelodysplastic Syndromes; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Ovarian Neoplasms | Details |
| MT-601 | MT601 | Phase 1 Clinical | Marker Therapeutics Inc | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details |
| Autologous NY-ESO-1-targeting dendritic cell vaccine (Roswell Park Cancer Institute) | DEC-205-NY-ESO-1; vCP2292; VCP-2292 | Phase 2 Clinical | Roswell Park Cancer Institute | Ovarian Neoplasms; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
This web search service is supported by Google Inc.
A-Z
